Corrigendum to "APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis" [Atherosclerosis 240/1 (2015) 98-104] DOI: 10.1016/j.atherosclerosis.2015.03.008;APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis

Atherosclerosis

Volumn 240, Issue 1, 2015, Pages 98-104

  Guardiola, Montse ^a,b   Cofán, Montserrat ^c,d   de Castro Oros, Isabel ^e   Cenarro, Ana ^e   Plana, Núria ^a,b   Talmud, Philippa J ^f   Masana, Lluís ^a,b   Ros, Emilio ^c,d   Civeira, Fernando ^e   Ribalta, Josep ^a,b  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

APOA5; Atherogenic dyslipidemia; IMT; NMR; Polymorphisms

Indexed keywords

APOLIPOPROTEIN A5; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A; BIOLOGICAL MARKER;

ADULT; ALLELE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; ATHEROSCLEROSIS; DYSLIPIDEMIA; FEMALE; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; OBESITY; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; ASYMPTOMATIC DISEASE; BLOOD; CAROTID ARTERY DISEASES; CLINICAL TRIAL; COMORBIDITY; DYSLIPIDEMIAS; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERWEIGHT; PHENOTYPE; RISK FACTOR; SPAIN; YOUNG ADULT;

ADULT; APOLIPOPROTEINS A; ASYMPTOMATIC DISEASES; BIOMARKERS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; COMORBIDITY; DYSLIPIDEMIAS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; OVERWEIGHT; PHENOTYPE; RISK FACTORS; SPAIN; TRIGLYCERIDES; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84924388034     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.05.008     Document Type: Erratum

References (31)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106:3143-3421.
2. Sarwar N., Sandhu M.S., Ricketts S.L., Butterworth A.S., Di Angelantonio E., Boekholdt S.M., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639.
3. Sniderman A.D., Dagenais G.R., Cantin B., Despres J.P., Lamarche B. High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol. Am. J. Cardiol. 2001, 87:792-793. A8.
4. Grundy S.M. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997, 95:1-4.
5. Despres J.P., Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444:881-887.
6. Adiels M., Olofsson S.O., Taskinen M.R., Boren J. Diabetic dyslipidaemia. Curr. Opin. Lipidol. 2006, 17:238-246.
7. Ford E.S., Li C., Zhao G., Pearson W.S., Mokdad A.H. Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. Diabetes Care 2008, 31:587-589.
8. Valdes S., Botas P., Delgado E., Alvarez F., Cadorniga F.D. Population-based incidence of type 2 diabetes in northern Spain: the Asturias Study. Diabetes Care 2007, 30:2258-2263.
9. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173.
10. Ribalta J., Figuera L., Fernandez-Ballart J., Vilella E., Castro Cabezas M., Masana L., et al. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin. Chem. 2002, 48:1597-1600.
11. Guardiola M., Ferre R., Salazar J., Alonso-Villaverde C., Coll B., Parra S., et al. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation. Clin. Chem. 2006, 52:1914-1919.
12. Hubacek J.A. Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. Clin. Chem. Lab. Med. 2005, 43:897-902.
13. Kathiresan S., Melander O., Guiducci C., Surti A., Burtt N.P., Rieder M.J., et al. Six New Loci Associated With Blood Low-density Lipoprotein Cholesterol, High-density Lipoprotein Cholesterol or Triglycerides in Humans 2008, vol. 40:189-197.
14. Beigneux A.P., Franssen R., Bensadoun A., Gin P., Melford K., Peter J., et al. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. 2009, 29:956-962.
15. Gin P., Beigneux A.P., Davies B., Young M.F., Ryan R.O., Bensadoun A., et al. Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to GPIHBP1 containing a G56R amino acid substitution. Biochim. Biophys. Acta 2007, 1771:1464-1468.
16. Zheng X.-Y., Zhao S.-P., Yan H. The role of apolipoprotein A5 in obesity and the metabolic syndrome. Biol. Rev. Camb. Philos. Soc. 2013, 88:490-498.
17. Otvos J.D., Jeyarajah E.J., Bennett D.W. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin. Chem. 1991, 37:377-386.
18. Jarauta E., Mateo-Gallego R., Gilabert R., Plana N., Junyent M., de Groot E., Cenarro A., Masana L., Ros E., Civeira F. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutr. Metab. Cardiovasc. Dis. 2012, 22(7):591-597.
19. Gomez-Gerique J.A., Gutierrez-Fuentes J.A., Montoya M.T., Porres A., Rueda A., Avellaneda A., et al. Lipid profile of the Spanish population: the DRECE (diet and risk of cardiovascular disease in Spain) study. DRECE study group. Med. Clin. (Barc.) 1999, 113:730-735.
20. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 2006, 26:847-870.
21. De Groot E., van Leuven S.I., Duivenvoorden R., Meuwese M.C., Akdim F., Bots M.L., et al. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat. Clin. Pract. Med. 2008, 5:280-288.
22. Wang J., Ban M.R., Kennedy B.A., Anand S., Yusuf S., Huff M.W., et al. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5:730-737.
23. Ariza M.-J., Sánchez-Chaparro M.-A., Barón F.-J., Hornos A.-M., Calvo-Bonacho E., Rioja J., et al. Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study. BMC Med. Genet. 2010, 11:66.
24. Skeggs J.W., Morton R.E. LDL and HDL enriched in triglyceride promote abnormal cholesterol transport. J.Lipid Res. 2002, 43:1264-1274.
25. Gonzàlez M., Ribalta J., Vives G., Iftimie S., Ferré R., Plana N., et al. Nuclear magnetic resonance lipoprotein subclasses and the APOE genotype influence carotid atherosclerosis in patients with systemic lupus erythematosus. J.Rheumatol. 2010, 37:2259-2267.
26. Ip S., Lichtenstein A.H., Chung M., Lau J., Balk E.M. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann. Intern. Med. 2009, 150:474-484.
27. Talmud P.J., Martin S., Taskinen M.R., Frick M.H., Nieminen M.S., Kesaniemi Y.A., et al. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J.Lipid Res. 2004, 45:750-756.
28. Lai C.Q., Demissie S., Cupples L.A., Zhu Y., Adiconis X., Parnell L.D., et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J.Lipid Res. 2004, 45:2096-2105.
29. Elosua R., Ordovas J.M., Cupples L.A., Lai C.Q., Demissie S., Fox C.S., et al. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J.Lipid Res. 2006, 47:990-996.
30. Sam S., Haffner S., Davidson M.H., D'Agostino R.B., Feinstein S., Kondos G., et al. Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes 2008, 57:2022-2027.
31. Evans D., Buchwald A., Beil F.U. The single nucleotide polymorphism -1131T>C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia. J.Mol. Med. (Berl.) 2003, 81:645-654.